Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement

被引：30

作者：

Lenihan, Daniel ^{[1
]}

Carver, Joseph ^{[2
]}

Porter, Charles ^{[3
]}

Liu, Jennifer E. ^{[4
]}

Dent, Susan ^{[5
]}

Thavendiranathan, Paaladinesh ^{[6
]}

Mitchell, Joshua D. ^{[1
]}

Nohria, Anju ^{[7
,8
]}

Fradley, Michael G. ^{[2
]}

Pusic, Iskra ^{[9
]}

Stockerl-Goldstein, Keith ^{[9
]}

Blaes, Anne ^{[10
]}

Lyon, Alexander R. ^{[11
,12
]}

Ganatra, Sarju ^{[13
]}

Lopez-Fernandez, Teresa ^{[14
]}

O'Quinn, Rupal ^{[2
]}

Minotti, Giorgio ^{[15
]}

Szmit, Sebastian ^{[16
]}

Cardinale, Daniela ^{[17
]}

Alvarez-Cardona, Jose ^{[1
]}

Curigliano, Giuseppe ^{[18
,19
]}

Neilan, Tomas G. ^{[20
]}

Herrmann, Joerg ^{[21
]}

机构：

[1] Washington Univ, Cardiooncol Ctr Excellence, St Louis, MO 63110 USA

[2] Univ Penn, Div Cardiol, Philadelphia, PA 19104 USA

[3] Univ Kansas, Med Ctr, Cardiooncol Unit, Cardiovasc Med, Kansas City, KS 66103 USA

[4] Mem Sloan Kettering Canc Ctr, Dept Med, Cardiol Serv, 1275 York Ave, New York, NY 10021 USA

[5] Duke Univ, Dept Med, Duke Canc Inst, Durham, NC USA

[6] Univ Toronto, Univ Hlth Network, Peter Munk Cardiac Ctr, Ted Rogers Program Cardiotoxic,Div Cardiol,Dept M, Toronto, ON, Canada

[7] Harvard Med Sch, Cardiooncol Program, Brigham & Womens Hosp, Boston, MA 02115 USA

[8] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA

[9] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA

[10] Univ Minnesota, Div Hematol Oncol, Minneapolis, MN USA

[11] Royal Brompton Hosp, Cardiooncol Serv, London, England

[12] Imperial Coll London, London, England

[13] Lahey Hosp & Med Ctr, Dept Cardiovasc Med, Cardiooncol Program, Burlington, MA USA

[14] La Paz Univ Hosp, La Paz Hosp Inst Hlth Res, Network Res Ctr Cardiovasc Dis, Div Cardiol,Cardiac Imaging & Cardiooncol Unit, Madrid, Spain

[15] Univ Campus Biomed, Dept Med, Rome, Italy

[16] European Hlth Ctr, Ctr Postgrad Med Educ, Dept Pulm Circulat Thromboembol Dis & Cardiol, Otwock, Poland

[17] IRCCS, European Inst Oncol, Cardiooncol Unit, Milan, Italy

[18] IRCCS, European Inst Oncol, Milan, Italy

[19] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy

[20] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Div Cardiol,Cardiooncol Program, Boston, MA 02115 USA

[21] Mayo Clin, Dept Cardiovasc Dis, 200 First St SW, Rochester, MN 55905 USA

来源：

CA-A CANCER JOURNAL FOR CLINICIANS | 2020年 / 70卷 / 06期

基金：

美国国家卫生研究院;

关键词：

best practice; cancer; cardiac safety; cardio-oncology; coronavirus disease 2019 (COVID-19); pandemic; recommendations; virus; TRASTUZUMAB-INDUCED CARDIOTOXICITY; LEFT-VENTRICULAR DYSFUNCTION; STAGE BREAST-CANCER; CLINICAL CHARACTERISTICS; CARDIOVASCULAR TOXICITY; RECEIVING TRASTUZUMAB; SARS CORONAVIRUS; AMERICAN SOCIETY; QT INTERVAL; BIOMARKERS;

D O I：

10.3322/caac.21635

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has given rise to a pandemic of unprecedented proportions in the modern era because of its highly contagious nature and impact on human health and society: coronavirus disease 2019 (COVID-19). Patients with cardiovascular (CV) risk factors and established CV disease (CVD) are among those initially identified at the highest risk for serious complications, including death. Subsequent studies have pointed out that patients with cancer are also at high risk for a critical disease course. Therefore, the most vulnerable patients are seemingly those with both cancer and CVD, and a careful, unified approach in the evaluation and management of this patient population is especially needed in times of the COVID-19 pandemic. This review provides an overview of the unique implications of the viral outbreak for the field of cardio-oncology and outlines key modifications in the approach to this ever-increasing patient population. These modifications include a shift toward greater utilization of cardiac biomarkers and a more focused CV imaging approach in the broader context of modifications to typical practice pathways. The goal of this strategic adjustment is to minimize the risk of SARS-CoV-2 infection (or other future viral outbreaks) while not becoming negligent of CVD and its important impact on the overall outcomes of patients who are being treated for cancer.

引用

页码：480 / 504

页数：25

共 118 条

[11] NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab [J].